Status:

COMPLETED

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Lead Sponsor:

Thomas Jefferson University

Collaborating Sponsors:

National Alliance for Research on Schizophrenia and Depression

Conditions:

Hyperhidrosis

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

The study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, terazosin (approved for hypertension), that will be added to the antid...

Eligibility Criteria

Inclusion

  • Age 18 - 75 years
  • Clinical diagnosis of a Depressive disorder (Diagnostic and Statistical Manual of Mental Disorders - IV-TR)
  • Presence of excessive sweating by self-report
  • The excessive sweating started after initiation of an antidepressant and, if treatment with the antidepressant was interrupted, did not persist for more than 4 weeks during that interruption
  • Treatment with the antidepressant is deemed to be clinically necessary due to substantial benefit from this antidepressant, and failure to respond to or tolerate an alternative
  • Excessive sweating has persisted for at least 4 weeks prior to baseline assessment
  • The excessive sweating is rated by the patient as at least moderately bothersome.
  • Episodes of excessive sweating occur at least twice a week for last 4 weeks

Exclusion

  • Presence of another known disease that could potentially cause excessive sweating
  • Failure to respond to antiadrenergic (reducing activity of the sympathetic nervous system) treatment in the past
  • Blood pressure less than 110 mm Hg systolic at the screening or baseline visits
  • Orthostatic hypotension by history or on assessment at the screening or baseline visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes).
  • Current antihypertensive treatment
  • History of significant cardiac disease, including coronary artery disease
  • Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM)
  • History of priapism (persistent and painful erection)

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2013

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT00449683

Start Date

March 1 2007

End Date

August 1 2013

Last Update

August 25 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Thomas Jefferson University, Department of Psychiatry

Philadelphia, Pennsylvania, United States, 19107